* IRadimed Corp IRMD.OQ IRMD.O is expected to show a
rise in
quarterly revenue when it reports results on February 4.
* The Winter Springs Florida-based company is expected to
report
a 36.1% increase in revenue to $11.632 million from $8.55
million a year ago, according to the mean estimate from 2
analysts, based on Refinitiv data.
* Refinitiv's mean analyst estimate for IRadimed Corp is
for
earnings of 21 cents per share. For the same quarter last year,
the company reported earnings of 7 cents per share.
* The current average analyst rating on the shares is
"strong buy"
and the breakdown of recommendations is 2 "strong buy" or
"buy," no "hold" and no "sell" or "strong sell."
* The mean earnings estimate of analysts was unchanged in
the last
three months.
* Wall Street's median 12-month price target for IRadimed
Corp is
$41, about 2.4% above its last closing price of $40.01.
This summary was machine generated February 2 at 13:56 GMT. All
figures in US dollars unless otherwise stated